drugset / Trial / NCT02226783

D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects

NCT02226783

Phase 1 Completed 37 enrolled Ardelyx
RandomizedCrossoverOpen-labelBasic science

Summary

Study to evaluate the effect of intake of food in comparison to fasting condition on pharmacodynamics of AZD1722 following a twice-daily administration of AZD1722 tablet formulation

Timeline

Start
2013-03
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Omeprazole Other / unclassified
Subject Tenapanor Small molecule 14 mg Oral
Subject Tenapanor Small molecule 56 mg Oral

Indications

No indication recorded.